Evan Seigerman
Stock Analyst at BMO Capital
(4.03)
# 528
Out of 5,072 analysts
149
Total ratings
54.55%
Success rate
10.61%
Average return
Main Sectors:
Stocks Rated by Evan Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TERN Terns Pharmaceuticals | Maintains: Outperform | $22 → $30 | $28.11 | +6.72% | 2 | Nov 18, 2025 | |
| LLY Eli Lilly and Company | Maintains: Outperform | $930 → $1,100 | $1,075.47 | +2.28% | 9 | Nov 6, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $557 → $530 | $433.61 | +22.23% | 16 | Aug 5, 2025 | |
| INCY Incyte | Maintains: Underperform | $52 → $60 | $104.46 | -42.56% | 13 | Jul 30, 2025 | |
| IRON Disc Medicine | Maintains: Outperform | $112 → $120 | $93.25 | +28.69% | 6 | May 12, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Market Perform | $96 → $115 | $152.16 | -24.42% | 15 | May 6, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $115 → $120 | $125.84 | -4.64% | 17 | Apr 17, 2025 | |
| BIIB Biogen | Maintains: Market Perform | $156 → $139 | $182.09 | -23.66% | 27 | Feb 13, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Market Perform | $57 → $61 | $49.20 | +23.98% | 11 | Nov 12, 2024 | |
| GPCR Structure Therapeutics | Initiates: Outperform | $40 | $35.81 | +11.70% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $40 | $10.00 | +300.00% | 1 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $757 → $788 | $780.19 | +1.00% | 17 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $8 → $2.5 | $8.03 | -68.87% | 2 | Aug 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $263 → $243 | $345.46 | -29.66% | 6 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $12 | $4.77 | +151.57% | 2 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $60 | $25.74 | +133.10% | 1 | Nov 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $30 | $1.53 | +1,860.78% | 3 | May 12, 2020 |
Terns Pharmaceuticals
Nov 18, 2025
Maintains: Outperform
Price Target: $22 → $30
Current: $28.11
Upside: +6.72%
Eli Lilly and Company
Nov 6, 2025
Maintains: Outperform
Price Target: $930 → $1,100
Current: $1,075.47
Upside: +2.28%
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Outperform
Price Target: $557 → $530
Current: $433.61
Upside: +22.23%
Incyte
Jul 30, 2025
Maintains: Underperform
Price Target: $52 → $60
Current: $104.46
Upside: -42.56%
Disc Medicine
May 12, 2025
Maintains: Outperform
Price Target: $112 → $120
Current: $93.25
Upside: +28.69%
Neurocrine Biosciences
May 6, 2025
Maintains: Market Perform
Price Target: $96 → $115
Current: $152.16
Upside: -24.42%
Gilead Sciences
Apr 17, 2025
Maintains: Outperform
Price Target: $115 → $120
Current: $125.84
Upside: -4.64%
Biogen
Feb 13, 2025
Maintains: Market Perform
Price Target: $156 → $139
Current: $182.09
Upside: -23.66%
Bristol-Myers Squibb Company
Nov 12, 2024
Maintains: Market Perform
Price Target: $57 → $61
Current: $49.20
Upside: +23.98%
Structure Therapeutics
Feb 28, 2023
Initiates: Outperform
Price Target: $40
Current: $35.81
Upside: +11.70%
Oct 14, 2022
Maintains: Outperform
Price Target: $30 → $40
Current: $10.00
Upside: +300.00%
Aug 4, 2022
Maintains: Outperform
Price Target: $757 → $788
Current: $780.19
Upside: +1.00%
Aug 2, 2022
Downgrades: Market Perform
Price Target: $8 → $2.5
Current: $8.03
Upside: -68.87%
Apr 28, 2022
Maintains: Market Perform
Price Target: $263 → $243
Current: $345.46
Upside: -29.66%
Mar 31, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $4.77
Upside: +151.57%
Nov 19, 2021
Initiates: Outperform
Price Target: $60
Current: $25.74
Upside: +133.10%
May 12, 2020
Maintains: Outperform
Price Target: $13 → $30
Current: $1.53
Upside: +1,860.78%